PF-05180999

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NamePF-05180999
Drug Alias NamePF-999PF-5180999Modified release PF-05180999MR PF-05180999PF-05180999
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 2A inhibitors
TargetsPhosphodiesterase 2A
Therapy Area/IndicationsSchizophreniaMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsSchizophreniaMigraine Disorders

Other Information

ATC CodeN/A
Related LinksN/A